Summary & Overview

HCPCS Level II J9306: Injection, pertuzumab, 1 mg

HCPCS Level II code J9306 denotes the injectable biologic pertuzumab measured per milligram (1 mg unit) and is used in oncology treatment regimens. As a billed drug code separate from chemotherapy administration, it is central to cost reporting, prior authorization workflows, and drug-specific billing practices across outpatient hospital and physician office settings. Nationally, accurate use of this code affects drug cost transparency, inventory management, and claims adjudication for biologic cancer therapies.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will find an overview of payer coverage considerations, common billing pairings with infusion administration codes, and contextual clinical use for pertuzumab in oncology care. The publication covers coding benchmarks and billing practices relevant to chemotherapy and biologic drug administration, common modifiers and related administration codes, and how J9306 typically appears on outpatient facility and office claims. Clinical context outlining the role of pertuzumab in cancer treatment is provided to aid accurate clinical-to-billing linkage.

Where required input elements were missing, the publication notes “Data not available in the input.” The content is intended for national audiences involved in oncology billing, revenue cycle, and clinical coding.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareJ9306HCPCS Level IIoncologypertuzumabchemotherapydrug billinginfusion servicesoutpatient hospitaloffice visits

Billing Code Overview

HCPCS Level II code J9306 represents an injection of pertuzumab, 1 mg, used as a biologic therapy in oncology. This code denotes the drug product itself rather than the infusion administration service.

Service Type: Oncology—chemotherapy/biologics

Typical Site of Service: Outpatient Hospital or Office (for example, Place of Service 11 or 22).

Clinical & Coding Specifications

Clinical Context

A 56-year-old female diagnosed with invasive breast carcinoma involving the nipple and areola presents to an outpatient oncology clinic for targeted HER2-directed therapy. The clinician orders intravenous pertuzumab administered as an injection dosed per weight; HCPCS Level II code J9306 (Injection, pertuzumab, 1 mg) is used for drug reporting. The patient arrives to an outpatient hospital infusion suite (Place of Service 22) or physician office (Place of Service 11). Nursing verifies orders, obtains baseline vitals and relevant labs (including cardiac function as clinically indicated), prepares and doses the biologic in the pharmacy, and the infusion/bolus is administered with concurrent documentation of lot number, NDC, amount dispensed, and any discarded remainder. The encounter includes chemotherapy administration services billed separately (for example, infusion administration codes), and modifier use is applied when drug waste or distinct procedural services occur.

Coding Specifications

Modifiers
JW: Used to report the drug amount discarded/not administered to any patient when a portion of a single-use vial is discarded and payor guidance permits reporting of wastage.
59: Used to report Distinct Procedural Service when a service or procedure is distinct or independent from other services performed on the same day; apply when clinical documentation supports separate and distinct service from other billed procedures.
Provider Taxonomies
207RH0003X: Hematology & Oncology Physician — Specialist providing systemic therapy for hematologic and oncologic conditions.
207RX0202X: Medical Oncology Physician — Specialist providing medical management and chemotherapy/biologic therapy for malignancies.
2084P0800X: Pediatric Hematology-Oncology Physician — Specialist providing hematology/oncology care for pediatric patients.
Notes on use
Billing for the drug product uses HCPCS Level II code J9306 to report pertuzumab by milligram; administration services (e.g., infusion codes) are billed separately using the appropriate chemotherapy administration CPT codes.

Related Codes

96413: Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug — Commonly billed for the initial intravenous administration visit when pertuzumab is administered; pairs with J9306 for drug reporting.
96415: Chemotherapy administration, intravenous infusion technique; each additional hour — Billed when infusion time for administration extends beyond the initial hour; applicable when extended infusion or concurrent agents prolong infusion time alongside J9306.
J9355: Injection, trastuzumab, 10 mg — A related HER2-targeted monoclonal antibody; may be administered in the same treatment regimen as pertuzumab (J9306) for dual HER2 blockade and is commonly documented together when clinically indicated.
J9312: Injection, rituximab, 10 mg — A monoclonal antibody for B-cell malignancies; listed as a related injectable biologic agent but used for different indications; not interchangeable with J9306.
Common combinations
J9306 is commonly reported alongside administration codes such as 96413 (initial infusion) and 96415 (additional hours) when applicable.
When partial vial waste occurs, append modifier JW to J9306 per payor policy.
Use of J9355 may occur in the same oncology treatment plan when trastuzumab is part of the regimen with pertuzumab; documentation should support concurrent administration.

Related Diagnoses

C50.011: Malignant neoplasm of nipple and areola, right female breast — Relevant as a primary breast cancer diagnosis for which HER2-targeted biologic therapy such as pertuzumab may be indicated.
C50.012: Malignant neoplasm of nipple and areola, left female breast — Relevant as a primary breast cancer diagnosis for which HER2-targeted biologic therapy such as pertuzumab may be indicated.

National Reimbursement Benchmarks

National mean rates for HCPCS Level II code J9306 vary substantially across payers. BUCA (representing a broad commercial aggregate) has a mean rate of $83.40 compared with Medicare at $0.00 based on the input — BUCA’s mean is therefore materially higher than Medicare in the provided values. Aetna’s mean rate of $298.74 is an outlier relative to the other commercial payers.

Rate dispersion measured as the difference between the 75th and 25th percentiles is tightest for Cigna Health (P75–P25 = $0.00) and very small for Blue Cross Blue Shield (P75–P25 = $2.00) and UnitedHealthcare (P75–P25 = $2.00). Aetna shows a very wide implied dispersion given the provided percentiles (P75–P25 = $7.17) driven by a low 25th percentile value relative to the mean. The table and chart below present the full breakdown.

National Mean Rates for HCPCS Level II code `J9306` by Payer

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.